Tertiary Nav - Press Releases Press ReleasesMedia Statements Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 5/4/11 AVI BioPharma Initiates Clinical Studies for Two RNA-Based Therapeutic Candidates for Treatment of Ebola and Marburg Viruses 4/28/11 AVI BioPharma Announces First Quarter 2011 Financial Results and Corporate Update Conference Call 4/26/11 AVI BioPharma to Present Company Overview at the Deutsche Bank 36th Annual Health Care Conference 4/12/11 AVI BioPharma to Present Data for RNA-Based Duchenne Muscular Dystrophy Drug Candidate at the 63rd Annual Meeting of the American Academy of Neurology 4/11/11 AVI BioPharma Receives Approval of Nonproprietary Name Eteplirsen for Lead Duchenne Muscular Dystrophy Therapeutic Candidate, AVI-4658 4/8/11 AVI BioPharma to Present Company Overview at the BioCentury Future Leaders in the Biotech Industry Conference 4/6/11 AVI BioPharma Announces Exercise of Underwriters' Over-Allotment Option and Closing of Public Offering of Common Stock 4/1/11 AVI BioPharma Prices $30.0 Million Public Offering of Common Stock 3/31/11 AVI BioPharma Announces Proposed Public Offering of Common Stock 3/28/11 AVI BioPharma Names Peter S. Linsley, Ph.D., Chief Scientific Officer Pagination First page « first Previous page ‹ previous … Page 55 Page 56 Page 57 Page 58 Current page 59 Page 60 Page 61 Page 62 Page 63 … Next page next › Last page last » Displaying 581 - 590 of 813 Toolkit Print Page | Email Alerts | RSS Feeds | Contacts
Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 5/4/11 AVI BioPharma Initiates Clinical Studies for Two RNA-Based Therapeutic Candidates for Treatment of Ebola and Marburg Viruses 4/28/11 AVI BioPharma Announces First Quarter 2011 Financial Results and Corporate Update Conference Call 4/26/11 AVI BioPharma to Present Company Overview at the Deutsche Bank 36th Annual Health Care Conference 4/12/11 AVI BioPharma to Present Data for RNA-Based Duchenne Muscular Dystrophy Drug Candidate at the 63rd Annual Meeting of the American Academy of Neurology 4/11/11 AVI BioPharma Receives Approval of Nonproprietary Name Eteplirsen for Lead Duchenne Muscular Dystrophy Therapeutic Candidate, AVI-4658 4/8/11 AVI BioPharma to Present Company Overview at the BioCentury Future Leaders in the Biotech Industry Conference 4/6/11 AVI BioPharma Announces Exercise of Underwriters' Over-Allotment Option and Closing of Public Offering of Common Stock 4/1/11 AVI BioPharma Prices $30.0 Million Public Offering of Common Stock 3/31/11 AVI BioPharma Announces Proposed Public Offering of Common Stock 3/28/11 AVI BioPharma Names Peter S. Linsley, Ph.D., Chief Scientific Officer Pagination First page « first Previous page ‹ previous … Page 55 Page 56 Page 57 Page 58 Current page 59 Page 60 Page 61 Page 62 Page 63 … Next page next › Last page last » Displaying 581 - 590 of 813
